Company: BIVIW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001520138-25-000144
Chunk: 40

Company: BIOVIE INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
    Ascites BIV201 Phase 2b 
    $-  
    $89,667  
    $(89,667)
  
    AD mild to moderate pivotal Phase 3 
     (26,091) 
     2,715,662  
     (2,741,753)
  
    Investigator-Initiated studies 
     -  
     1,928  
     (1,928)
  
    Other studies in development/cancelled 
     -  
     116,047  
     (116,047)

    $(26,091) 
    $2,923,304  
    $(2,949,395)

 23 

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $1.6 million and $2.0 million
for the three months ended March 31, 2025 and 2024, respectively. The net decrease in expenses of approximately $388,000 were primarily
attributed to decreases in directors’ compensation of approximately $201,000, executive teams’ compensation of $148,000 and
legal fees of approximately $121,000, offset by increased expenses comprising of increased audit, accounting and regulatory filing fees
of approximately $19,000, other consulting and professional fees of approximately $25,000, public and investor relations fees of $8,000
and miscellaneous expenses for website development, travel and other banking fees totaling approximately $23,000.

Other Income and Expense

Other income, net was approximately $200,000 compared
to other expense, net of $336,000, for the three months ended March 31, 2025 and 2024, respectively. The net decrease in other expense
of approximately $536,000 was comprised of the decrease in the change in fair value of the derivative liabilities of approximately $102,000,
offset by a decline in interest expense of approximately $624,000 due to the payoff of the notes payable on December 1, 2024, and an increase
in interest income of approximately $14,000.

Comparison of the nine months ended March 31, 2025 to the nine months
ended March 31, 2024

Net loss

The net loss for the nine months ended March 31,
2025 was approximately $14.1 million as compared to the net loss of $27.2 million for the nine months ended March 31, 202